Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $21.9 million.

  • Protalix BioTherapeutics' Total Current Liabilities fell 939.31% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 939.31%. This contributed to the annual value of $25.6 million for FY2024, which is 4372.72% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Total Current Liabilities stood at $21.9 million for Q3 2025, which was down 939.31% from $24.1 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Total Current Liabilities' 5-year high stood at $96.2 million during Q2 2021, with a 5-year trough of $21.9 million in Q3 2025.
  • Its 5-year average for Total Current Liabilities is $40.1 million, with a median of $33.2 million in 2021.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Total Current Liabilities tumbled by 6783.28% in 2022, and later skyrocketed by 15086.33% in 2024.
  • Protalix BioTherapeutics' Total Current Liabilities (Quarter) stood at $33.2 million in 2021, then decreased by 2.25% to $32.4 million in 2022, then skyrocketed by 40.4% to $45.5 million in 2023, then plummeted by 43.73% to $25.6 million in 2024, then decreased by 14.35% to $21.9 million in 2025.
  • Its Total Current Liabilities stands at $21.9 million for Q3 2025, versus $24.1 million for Q2 2025 and $24.3 million for Q1 2025.